Navigation Links
Medicago to present at the U.S. Department of Health and Human Services' Global Health Security Initiative Workshop
Date:11/4/2009

QUEBEC CITY, Nov. 4 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it received an invitation from the U.S. Department of Health and Human Services (HHS) to present at the Global Health Security Initiative Workshop (GHSI) on November 5, 2009 at 2:40 pm (EST) at the Fairfax at Embassy Row Hotel, Washington, D.C. During a session entitled Diagnostics and Vaccine Development Platforms, Medicago will discuss its ability to potentially improve the speed, capacity and cost of influenza vaccine production with its proprietary plant-based manufacturing platform and VLP technology.

The GHSI is an international, high-level forum for like-minded countries to discuss public health preparedness for chemical, biological, and radiological/nuclear (CBRN) threats as well as pandemic influenza. Amongst the GHSI policy priorities, the GHSI partners agreed on the need to build a global infrastructure for medical countermeasures (MCM). This year's workshop will provide an international opportunity for academia and industry partners to discuss research and development programs, products and new technologies as a first step towards coordinating preparedness efforts.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release

SOURCE Medicago Inc.


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
2. Medicago begins human clinical testing with its avian flu pandemic vaccine
3. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
4. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
5. Medicago succesfully expresses VLP antigen for A H1N1 strain
6. Medicago initiates work on Swine Flu strain
7. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
8. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
9. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
10. Additional Data From Fidaxomicins Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
11. ViroPharma to Present at Three November Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... Grand Bahama (PRWEB) , ... July 26, 2017 , ... ... Regenerative Medicine , which is licensed by the Bahamas’ National Stem Cell Ethics Committee ... (MBBS) from the University of the West Indies. He went on to complete residency ...
(Date:7/26/2017)... - Caprion Biosciences Inc., a world leading specialty CRO announced the ... of early stage (latent) Mycobacterium tuberculosis (Mtb) infection using state-of-the-art ... platform. ... Caprion Biosciences Inc. (CNW Group/Caprion Biosciences) ... The new data, recently published in ...
(Date:7/26/2017)... ... July 25, 2017 , ... The leading Regenerative Veterinary Medicine ... cell therapy has been used on more than 13,000 animals. VetStem was ... fatal injuries to tendons and ligaments. , In 2003 VetStem signed a worldwide ...
(Date:7/26/2017)... ... July 26, 2017 , ... Spectral ... we face every day. This unique capability combines high resolution imaging with ... manufacturers to deliver unprecedented datasets for chemical analysis, quality control, and decision-making. , ...
Breaking Biology Technology:
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft System ... over the next decade to reach approximately $14.21 billion by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):